Cookie policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read our Privacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

Chronic Total Occlusion

​Comprehensive treatment solutions for Chronic Total Occlusion

Chronic Total Occlusion

 

 

 

 

 

 

 

 

Terumo Receives CE Mark Approval for the Line Extension on Drug-Eluting Stent, Ultimaster® to Advance the Treatment of Coronary Artery Diseasehttps://www.terumo-europe.com/en-emea/news/terumo-receives-ce-mark-approval-for-the-line-extension-on-drug-eluting-stent-ultimaster-to-advance-the-treatment-of-coronary-artery-diseaseTerumo Receives CE Mark Approval for the Line Extension on Drug-Eluting Stent, Ultimaster® to Advance the Treatment of Coronary Artery DiseaseLeuven, Belgium03/12/2014 23:00:00
Terumo Announces Exclusive Acquisition Right Agreement with French Bioresorbable Scaffold Company, “ART”https://www.terumo-europe.com/en-emea/news/terumo-announces-exclusive-acquisition-right-agreement-with-french-bioresorbable-scaffold-company-artTerumo Announces Exclusive Acquisition Right Agreement with French Bioresorbable Scaffold Company, “ART”Tokyo, Japan13/03/2014 23:00:00
Terumo Receives CE Mark for Its New Drug-eluting Stent, Ultimaster™https://www.terumo-europe.com/en-emea/news/terumo-receives-ce-mark-for-its-new-drug-eluting-stent-ultimasteTerumo Receives CE Mark for Its New Drug-eluting Stent, Ultimaster™Leuven, Belgium17/02/2014 23:00:00

 

 

CCT 2018https://www.terumo-europe.com/en-emea/Events/CCT 2018.aspxCCT 2018Japan24/10/2018 22:00:0027/10/2018 15:06:00Kobehttps://cct.gr.jp/meetings.html, https://cct.gr.jp/meetings.html